CMS Authority For Least Costly Alternative On Drugs Coming Soon – Sen. Roberts
This article was originally published in The Pink Sheet Daily
Executive Summary
Kansas senator expresses concern that LCA authority, combined with comparative effectiveness, could blur the lines between FDA and CMS.
You may also be interested in...
Medicare Coverage For FOBs: MedPAC Weighs Least Costly Alternative, Coding Options
The Medicare Payment Advisory Commission is taking up payment issues for follow-on biologics as legislation establishing a regulatory pathway for approving such products gathers momentum in Congress.
Medicare Coverage For FOBs: MedPAC Weighs Least Costly Alternative, Coding Options
The Medicare Payment Advisory Commission is taking up payment issues for follow-on biologics as legislation establishing a regulatory pathway for approving such products gathers momentum in Congress.
Comparative Effectiveness In U.S. Will Not Be NICE, OMB’s Orszag says
The U.S. will not follow the UK’s model of having a bureaucratic organization making cost-effectiveness decisions, OMB director tells Congress.